Shanghai Hengrundasheng Biotechnology

Hrain Biotechnology (Shanghai Hengrun Dasheng Biotechnology) is an innovative Chinese biopharmaceutical company specializing in the research, development, and manufacturing of breakthrough immune cell therapies. The company's proprietary pipeline is built around Chimeric Antigen Receptor T-cell (CAR-T) and Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies, targeting hematologic malignancies and solid tumors. In July 2025, Hrain's lead CD19-targeted CAR-T product, HICARA® (ranicabtagene autoleucel), was approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). Operating from its state-of-the-art GMP-compliant manufacturing facility in Shanghai, Hrain continues to advance multiple clinical-stage candidates to address unmet medical needs in oncology.